Von Willebrand disease

Results: 277



#Item
1en77  Original Article Improved Handling of Synonymous SNOMED CT Concepts used in HL7 Version 3 by the Example of the Von Willebrand Disease

en77 Original Article Improved Handling of Synonymous SNOMED CT Concepts used in HL7 Version 3 by the Example of the Von Willebrand Disease

Add to Reading List

Source URL: www.ejbi.org

Language: English - Date: 2017-06-28 11:48:09
    2News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

    News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

    Add to Reading List

    Source URL: www.cslbehring.at

    Language: English - Date: 2013-11-18 05:52:30
    3News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

    News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

    Add to Reading List

    Source URL: www.cslbehring.at

    Language: English - Date: 2013-11-18 05:52:29
    4CrossMark_Color_flat+click

    CrossMark_Color_flat+click

    Add to Reading List

    Source URL: www.biophysik.physik.uni-muenchen.de

    Language: English - Date: 2016-01-25 04:04:04
    5HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFSTYLA safely and effectively. See full prescribing information for AFSTYLA. ----------------------------DOSAGE FOR

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFSTYLA safely and effectively. See full prescribing information for AFSTYLA. ----------------------------DOSAGE FOR

    Add to Reading List

    Source URL: labeling.cslbehring.com

    Language: English - Date: 2016-05-26 14:29:43
    6Major Therapeutic Products Marketed by CSL Behring Bleeding Disorders Coagulation therapies are used to treat bleeding disorders such as hemophilia, Von Willebrand Disease and more. 

    Major Therapeutic Products Marketed by CSL Behring Bleeding Disorders Coagulation therapies are used to treat bleeding disorders such as hemophilia, Von Willebrand Disease and more. 

    Add to Reading List

    Source URL: www.cslbehring.com

    Language: English - Date: 2016-03-15 19:08:23
      7UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows  Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

      UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

      Add to Reading List

      Source URL: www.nektar.com

      Language: English - Date: 2015-07-30 13:12:07
      8Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects

      Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects

      Add to Reading List

      Source URL: www.thrombosisjournal.com

      Language: English
      9the Source mag a zine of the Pl a sma Protein Therapeut ic s Industry  Plasma Protein TherapieS  Summer

      the Source mag a zine of the Pl a sma Protein Therapeut ic s Industry  Plasma Protein TherapieS Summer

      Add to Reading List

      Source URL: www.pptaglobal.org

      Language: English - Date: 2015-01-13 05:38:57
      10Summary and Conclusions  Treatment of Hemophilia A and B and von Willebrand Disease A Systematic Review

      Summary and Conclusions Treatment of Hemophilia A and B and von Willebrand Disease A Systematic Review

      Add to Reading List

      Source URL: www.sbu.se

      - Date: 2011-06-09 06:10:12